Erratum: Schisandrin B Attenuates Cancer Invasion and Metastasis Via Inhibiting Epithelial-Mesenchymal Transition (PLoS ONE (2012) 7:7 (e40480) DOI: 10.1371/journal.pone.0040480);Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Liu, Zhen ^a   Zhang, Biao ^a   Liu, Kun ^b   Ding, Zonghui ^a   Hu, Xun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SCHIZANDRIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BONE METASTASIS; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; SURVIVAL TIME;

MURINAE; MUS;

EID: 84864343378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0275601     Document Type: Erratum

References (55)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
2. America Cancer Society (2012) Cancer Facts & Figures 2012. Atlanta: American Cancer Society pp. 9-11.
3. Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K, (2012) Death causes in breast cancer patients. Ann Oncol 23: 604-610.
4. Lorusso G, Ruegg C, (2012) New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol: in press.
5. Chaffer CL, Weinberg RA, (2011) A perspective on cancer cell metastasis. Science 331: 1559-1564.
6. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
7. Mego M, Mani SA, Cristofanilli M, (2010) Molecular mechanisms of metastasis in breast cancer-clinical applications. Nature reviews Clinical oncology 7: 693-701.
8. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nature reviews Cancer 9: 274-284.
9. Eccles SA, Welch DR, (2007) Metastasis: recent discoveries and novel treatment strategies. Lancet 369: 1742-1757.
10. Sun M, Xu X, Lu Q, Pan Q, Hu X, (2007) Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 246: 300-307.
11. Li L, Pan Q, Sun M, Lu Q, Hu X, (2007) Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci 80: 741-748.
12. Pan Q, Lu Q, Zhang K, Hu X, (2006) Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 58: 99-106.
13. Qiangrong P, Wang T, Lu Q, Hu X, (2005) Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 335: 406-411.
14. Huang M, Jin J, Sun H, Liu GT, (2008) Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 62: 1015-1026.
15. Fong WF, Wan CK, Zhu GY, Chattopadhyay A, Dey S, et al. (2007) Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes. Planta Med 73: 212-220.
16. Li L, Lu Q, Shen Y, Hu X, (2006) Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol 71: 584-595.
17. Xu Y, Liu Z, Sun J, Pan Q, Sun F, et al. (2011) Schisandrin B prevents Doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PloS one 6: e28335.
18. Li L, Pan Q, Han W, Liu Z, Hu X, (2007) Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clin Cancer Res 13: 6753-6760.
19. Giridharan VV, Thandavarayan RA, Bhilwade HN, Ko KM, Watanabe K, et al. (2012) Schisandrin B, attenuates cisplatin-induced oxidative stress, genotoxicity and neurotoxicity through modulating NF-kappaB pathway in mice. Free Radic Res 46: 50-60.
20. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, et al. (2009) Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res 37: 5678-5689.
21. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, et al. (1998) Short-term primary culture of epithelial cells derived from human breast tumours. British journal of cancer 78: 1421-1429.
22. Heppner GH, Miller FR, Shekhar PM, (2000) Nontransgenic models of breast cancer. Breast cancer research: BCR 2: 331-334.
23. Pulaski BA, Ostrand-Rosenberg S, (2001) Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20: Unit 20 22.
24. Sabel MS, Su G, Griffith KA, Chang AE, (2010) Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 122: 325-336.
25. Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, et al. (2006) Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66: 6327-6335.
26. Box GM, Eccles SA, (2011) Simple experimental and spontaneous metastasis assays in mice. Methods Mol Biol 769: 311-329.
27. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, et al. (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature biotechnology 28: 341-347.
28. Office of Animal Care and Use (2011) Guidelines for Endpoints in Animal Study Proposals. Available: http://oacu.od.nih.gov/ARAC/.
29. Lee YH, Albig AR, Regner M, Schiemann BJ, Schiemann WP, (2008) Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 29: 2243-2251.
30. Safholm A, Tuomela J, Rosenkvist J, Dejmek J, Harkonen P, et al. (2008) The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 14: 6556-6563.
31. Muller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
32. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, et al. (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5: e10365.
33. Han W, Li L, Qiu S, Lu Q, Pan Q, et al. (2007) Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6: 1641-1649.
34. Wu H, Ding Z, Hu D, Sun F, Dai C, et al. (2012) Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol 227: 189-199.
35. Ding W, You H, Dang H, LeBlanc F, Galicia V, et al. (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 52: 945-953.
36. Ottewell PD, Coleman RE, Holen I, (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast cancer research and treatment 96: 101-113.
37. Pulaski BA, Ostrand-Rosenberg S, (2001) Mouse 4T1 breast tumor model. Current protocols in immunology/edited by John E Coligan [et al] Chapter 20: Unit 20 22.
38. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, et al. (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 728-734.
39. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
40. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA, (2009) Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449.
41. Kang Y, Massague J, (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279.
42. Lacroix M, Leclercq G, (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast cancer research and treatment 83: 249-289.
43. Price JE, Polyzos A, Zhang RD, Daniels LM, (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer research 50: 717-721.
44. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu WP, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
45. Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, et al. (2011) Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer research 71: 7705-7715.
46. Zavadil J, Bottinger EP, (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
47. Sleeman J, Steeg PS, (2010) Cancer metastasis as a therapeutic target. Eur J Cancer 46: 1177-1180.
48. Pan SY, Dong H, Han YF, Li WY, Zhao XY, et al. (2006) A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacol 537: 200-204.
49. Park EJ, Chun JN, Kim SH, Kim CY, Lee HJ, et al. (2012) Schisandrin B suppresses TGFbeta1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem Pharmacol 83: 378-384.
50. Ip SP, Ko KM, (1996) The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Biochem Pharmacol 52: 1687-1693.
51. Hancke JL, Burgos RA, Ahumada F, (1999) Schisandra chinensis (Turcz.) Baill. Fitoterapia 70: 451-471.
52. Ebos JM, Kerbel RS, (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8: 210-221.
53. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
54. Man S, Zhang Y, Gao W, Yan L, Ma C, (2008) Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma. Clin Exp Metastasis 25: 855-864.
55. Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, et al. (2005) The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 65: 4929-4938.